According to the latest market research report title “Next Generation Immunotherapy Market By Type (Vaccines, Immune Checkpoint Modulators, CAR-T Cell Therapy, Tumor-Infiltrating Lymphocytes [TILs] Therapy, Bispecific Antibodies, Oncolytic Virus Therapy, Others), By Route of Administration (Intravenous, Intratumoral, Subcutaneous, Oral), By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cancer Research Centers), By Region (North America,, South America,, Europe,, Middle East & Africa,, Asia-Pacific)–Forecast to 2029″, published by MarkNtel Advisors, Global Next Generation Immunotherapy Market is projected to grow at a CAGR of around 7.5% during the forecast period, i.e., 2024-29.
The data present in the report exhibit from the historic years (2019-22) and the base year (2023) to put together estimations for the forecast period (2024-29). In the study, our researchers put together reliable, unbiased, and accurate data to enlighten investors about fluctuations in the industry & anticipations on what to expect in the future. Since the industry is dynamic and highly fragmented, this report enables the prominent players to make strategic moves associated with their investments in the coming years.
Request for Sample Report: https://www.marknteladvisors.com/query/request-sample/next-generation-immunotherapy-market.html
Global Next Generation Immunotherapy Market Challenge:
Reimbursement Challenges in the Global Next Generation Immunotherapy Market– The high costs associated with innovative therapies have been raising concerns regarding their affordability and reimbursement. The personalized and complex nature of next-generation immunotherapies has contributed to their high price tags, which were creating challenges for healthcare systems, payers, and patients in securing reimbursement and access. Reimbursement policies and mechanisms were not fully developed or adapted to account for the unique characteristics of these therapies, considering factors such as long-term patient outcomes, cost-effectiveness, and the potential for cure or prolonged remission. For instance,
- In 2021, as per the Centres for Medicare & Medicaid Services (CMS), in the inpatient setting, the current reimbursement model for CAR-T therapy falls short of covering the high costs, leading to potential financial losses for hospitals treating Medicare patients.
One of the key issues with the current reimbursement model in the inpatient setting has been that it fails to account for the full cost spectrum of next-generation immunotherapies like CAR-T therapy, including the complex and resource-intensive care required for patient management. Hence, this financial strain has not only been impacting patient’s access to CAR-T therapy but has also been affecting the sales of next-generation immunotherapies across the globe.
Next Generation Immunotherapy Market Segmentation
The Next Generation Immunotherapy Market is highly robust and fragmented into numerous segments;
By Type
-Vaccines- Market Size & Forecast 2019-2029F, USD Million
–mRNA Vaccines- Market Size & Forecast 2019-2029F, USD Million
–DNA Vaccines- Market Size & Forecast 2019-2029F, USD Million
–Protein Vaccines- Market Size & Forecast 2019-2029, USD Million
–Others (Viral Vector Vaccines, Nanoparticle Vaccines, etc.)- Market Size & Forecast 2019-2029, USD Million
-Immune Checkpoint Modulators- Market Size & Forecast 2019-2029F, USD Million
-CAR-T Cell Therapy- Market Size & Forecast 2019-2029F, USD Million
-Tumor-Infiltrating Lymphocytes (TILs) Therapy- Market Size & Forecast 2019-2029F, USD Million
-Bispecific Antibodies- Market Size & Forecast 2019-2029F, USD Million
-Oncolytic Virus Therapy- Market Size & Forecast 2019-2029F, USD Million
-Others (Antibody-drug Conjugates, ACE Inhibitors, etc.)- Market Size & Forecast 2019-2029F, USD Million
By Route of Administration
-Intravenous- Market Size & Forecast 2019-2029F, USD Million
-Intratumoral- Market Size & Forecast 2019-2029F, USD Million
-Subcutaneous- Market Size & Forecast 2019-2029F, USD Million
-Oral- Market Size & Forecast 2019-2029F, USD Million
By Therapeutic Area
-Oncology- Market Size & Forecast 2019-2029F, USD Million
-Autoimmune Diseases- Market Size & Forecast 2019-2029F, USD Million
-Infectious Diseases- Market Size & Forecast 2019-2029F, USD Million
-Inflammatory Diseases- Market Size & Forecast 2019-2029F, USD Million
-Others (Neurological Disorders, B-cell Malignancies, etc.) – Market Size & Forecast 2019-2029F, USD Million
By End User
-Hospitals- Market Size & Forecast 2019-2029F, USD Million
-Specialty Clinics- Market Size & Forecast 2019-2029F, USD Million
-Ambulatory Surgical Centres- Market Size & Forecast 2019-2029F, USD Million
-Cancer Research Centres- Market Size & Forecast 2019-2029F, USD Million
By Region
-North America
-South America
-Europe
-Middle East & Africa
-Asia-Pacific
Click here for a more detailed explanation: https://www.marknteladvisors.com/research-library/next-generation-immunotherapy-market.html
Key Players Operating in the Next Generation Immunotherapy Market: –
MacroGenics
-Business Description
-Product Portfolio
-Strategic Alliances or Partnerships
-Recent Developments
-Financial Details
-Others
AbbVie Inc.
-Business Description
-Product Portfolio
-Strategic Alliances or Partnerships
-Recent Developments
-Financial Details
-Others
Pfizer Inc.
-Business Description
-Product Portfolio
-Strategic Alliances or Partnerships
-Recent Developments
-Financial Details
-Others
Key Questions Answered:
- What is the projected CAGR of the Next Generation Immunotherapy Market during the forecast period?
- Which segment is expected to lead the Next Generation Immunotherapy Market?
- Who are the prominent players driving market growth?
Key Offerings:
- Market Share, Size, and Revenue Forecast
- Market Dynamics: Growth drivers, restraints, investment opportunities, and key trends
- Landscape: Leading key players and other prominent participants
About MarkNtel Advisors
MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
Using such information, our clients can identify attractive investment opportunities & strategize their moves to yield higher ROI (Return of Interest) through an early mover advantage with top-management approaches.
We understand the mounting & diverse needs of our clients. Hence, our analysts focus on emerging industries to provide services that fulfilled their assessment of the current & future industry potential, identify white spaces & hotspots, & venture into new geographies or business segments in the future.
Contact Us –
Call: 📞 +1 628 895 8081, +91 120 4278433
Email: 📧 sales@marknteladvisors.com
Visit to know more: 🌐 www.marknteladvisors.com
